HK1223917A1 - 作為 激酶抑制劑的 -二氫苯並呋喃- -基化合物 - Google Patents

作為 激酶抑制劑的 -二氫苯並呋喃- -基化合物

Info

Publication number
HK1223917A1
HK1223917A1 HK16112043.4A HK16112043A HK1223917A1 HK 1223917 A1 HK1223917 A1 HK 1223917A1 HK 16112043 A HK16112043 A HK 16112043A HK 1223917 A1 HK1223917 A1 HK 1223917A1
Authority
HK
Hong Kong
Prior art keywords
dyrk
dihydrobenzofuran
compounds
kinase inhibitors
dyrk kinase
Prior art date
Application number
HK16112043.4A
Other languages
English (en)
Inventor
Johann Leban
Mirko Zaja
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of HK1223917A1 publication Critical patent/HK1223917A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16112043.4A 2013-06-18 2016-10-19 作為 激酶抑制劑的 -二氫苯並呋喃- -基化合物 HK1223917A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13172577 2013-06-18
PCT/EP2014/062774 WO2014202638A1 (en) 2013-06-18 2014-06-17 2,3-dihydrobenzofuran-5-yl compounds as dyrk kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1223917A1 true HK1223917A1 (zh) 2017-08-11

Family

ID=48628358

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112043.4A HK1223917A1 (zh) 2013-06-18 2016-10-19 作為 激酶抑制劑的 -二氫苯並呋喃- -基化合物

Country Status (10)

Country Link
US (1) US10005769B2 (zh)
EP (1) EP3010920A1 (zh)
JP (1) JP6619731B2 (zh)
CN (1) CN105555785B (zh)
AU (1) AU2014283378B2 (zh)
CA (1) CA2915566C (zh)
HK (1) HK1223917A1 (zh)
MX (1) MX2015017512A (zh)
TW (1) TWI705963B (zh)
WO (1) WO2014202638A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
WO2017013210A1 (en) * 2015-07-21 2017-01-26 4Sc Ag Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds
EP3246330A1 (en) * 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
CN111936490A (zh) * 2017-11-20 2020-11-13 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
US11866427B2 (en) 2018-03-20 2024-01-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019193577A1 (en) * 2018-04-06 2019-10-10 Telefonaktiebolaget Lm Ericsson (Publ) Narrowband positioning reference signal generation for correlation properties
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
KR102325607B1 (ko) * 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
EP4161656A4 (en) 2020-06-05 2024-06-19 Kinnate Biopharma Inc. INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
CN113444081B (zh) * 2021-07-30 2022-07-05 浙江大学 噻二唑酰胺类化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033072A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
MX2007003115A (es) * 2004-09-20 2007-07-16 4Sc Ag Novedosos inhibidores heterociclicos del nf-kb.
BRPI0614188A2 (pt) * 2005-07-29 2011-03-15 4Sc Ag compostos inibidores heterocìclicos de nf-kappab, uso dos mesmos e composição farmacêutica
CA2632021A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
EP1834954A1 (en) * 2006-03-15 2007-09-19 4Sc Ag Thiazoles as NF-kB Inhibitors (proteasome inhibitors)
JP2009529555A (ja) * 2006-03-15 2009-08-20 ４エスツェー アクチェンゲゼルシャフト 新規複素環式ＮＦ−κＢ阻害薬
EP2078003B1 (en) * 2006-10-31 2017-03-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
WO2008116919A1 (en) * 2007-03-27 2008-10-02 4Sc Ag Pharmaceutical composition comprising a cytokine
WO2009037357A1 (en) * 2007-09-19 2009-03-26 4Sc Ag Benzimidazole nf- kappab inhibitors
EP2070916A1 (de) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2915566C (en) 2021-12-21
CN105555785B (zh) 2019-03-01
CN105555785A (zh) 2016-05-04
AU2014283378B2 (en) 2018-09-27
US20160137637A1 (en) 2016-05-19
TWI705963B (zh) 2020-10-01
EP3010920A1 (en) 2016-04-27
AU2014283378A1 (en) 2016-01-07
CA2915566A1 (en) 2014-12-24
WO2014202638A9 (en) 2016-03-03
NZ714958A (en) 2021-06-25
JP2016521762A (ja) 2016-07-25
TW201536777A (zh) 2015-10-01
MX2015017512A (es) 2016-06-30
US10005769B2 (en) 2018-06-26
JP6619731B2 (ja) 2019-12-11
WO2014202638A1 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
HRP20181287T1 (hr) Aminoheteroarilbenzamidi kao inhibitori kinaze
HK1223917A1 (zh) 作為 激酶抑制劑的 -二氫苯並呋喃- -基化合物
HK1208442A1 (zh) 作為 激酶抑制劑的取代的吡咯並嘧啶基氨基－苯並噻唑酮
HK1220459A1 (zh) 激酶抑制劑
ZA201406688B (en) Serine, threonine kinase inhibitors
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1209277A1 (zh) -三嗪- -甲酰胺激酶抑制劑
HK1219104A1 (zh) 激酶抑制劑
EP3076789A4 (en) Novel compounds as jnk kinase inhibitors
EP2976341A4 (en) ACYCLIC CYANOETHYLPYRAZOLPYRIDONE AS JANUSKINASEINHIBITORS
EP2976339A4 (en) GEPENALLY SUBSTITUTED CYANOETHYLPYRAZOLOPYRIDONES AS INHIBITORS OF JANUS KINASE
EP2968331A4 (en) PYRROLOPYRIMIDINE COMPOUNDS AS KINASEINHIBITORS
HK1217654A1 (zh) 作爲激酶抑制劑的呋喃酮化合物
HK1222386A1 (zh) 作爲詹納斯激酶的抑制劑的 -氰基甲基酰胺
GB201522245D0 (en) Compounds useful as kinase inhibitors
GB201307155D0 (en) Kinase inhibitors